Brevan Howard Capital Management’s Dyne Therapeutics DYN Stock Holding History

Brevan Howard Capital Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$827K	Hold	37,214	–	–	0.01%	1168
2026 Q1	$675K	Sell	37,214 -120,755	-76%	-$2.08M	0.01%	1120
2025 Q4	$3.09M	Buy	157,969 +98,667	+166%	+$1.87M	0.03%	343
2025 Q3	$750K	Buy	59,302 +44,179	+292%	+$504K	﹤0.01%	1054
2025 Q2	$144K	Buy	+15,123	New	+$166K	﹤0.01%	1761
2025 Q1	–	Sell	-28,781	Closed	-$678K	–	1232
2024 Q4	$678K	Buy	+28,781	New	+$851K	﹤0.01%	530
2024 Q3	–	Sell	-10,053	Closed	-$355K	–	1211
2024 Q2	$355K	Buy	+10,053	New	+$292K	﹤0.01%	720

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Brevan Howard Capital Management's DYN Position: Q2 2026 in Review

Brevan Howard Capital Management held its Dyne Therapeutics (DYN) position steady in Q2 2026 at 37,214 shares worth $827K. The position accounts for 0.01% of the portfolio, ranked #1168.

Brevan Howard Capital Management first reported a position in DYN in Q2 2024 and has held it in 7 quarters since. The position peaked at $3.09M in Q4 2025. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

Brevan Howard Capital Management held 37,214 shares of Dyne Therapeutics worth $827K as of Q2 2026.
Brevan Howard Capital Management left its Dyne Therapeutics share count unchanged in Q2 2026.
Dyne Therapeutics made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1168 holding.
Brevan Howard Capital Management first reported a position in Dyne Therapeutics in Q2 2024 and has held it in 7 quarters since.
Brevan Howard Capital Management's Dyne Therapeutics position peaked at $3.09M in Q4 2025.
245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.